search results for 
Logo

Group sales and earnings

With its international production and sales platform and its market-oriented products and services, the Fresenius Group is well positioned for continued growth in the coming years. Specific opportunities for profitable growth are indicated by the developments described in the section “Health Care Sector and Markets.”

While our traditional markets in Europe and North America are growing at average low- to mid-single-digit rates, we see stronger growth potential in the Asia-Pacific region and in Latin America. Here the demand for our life-saving and life-sustaining products continues to be high as access to medical care is still limited. This will also be reflected in sales.

In 2013, we therefore expect to increase Group sales by 7% to 10% in constant currency. We also expect to increase Group net income1 once again in 2013. We aim to achieve this through the growth in sales discussed and by ongoing measures to optimize costs. Despite a market environment that continues to be marked by cost containment and price pressure, we expect to increase net income1 by 7% to 12% in constant currency. On this basis Fresenius expects to reach 2014 Group net income target of more than €1 billion one year ahead of plan (before special items).

GROUP FINANCIAL TARGETS


  Targets 2013 Fiscal year 2012
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (~€50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.
Sales growth (in constant currency) 7 - 10% €19,290 m
Net income1, growth (in constant currency) 7 - 12% €938 m
Capital expenditure ~5% of sales €1,007 m
Dividend Profit-driven dividend policy Proposal +16% per share

  Targets 2013 Fiscal year 2012
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (~€50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.
Sales growth (in constant currency) 7 - 10% €19,290 m
Net income1, growth (in constant currency) 7 - 12% €938 m
Capital expenditure ~5% of sales €1,007 m
Dividend Profit-driven dividend policy Proposal +16% per share

QUICKFINDER

History

Tools